相关临床试验
1428
179 进行中
药物批准
1
批准总数
监管机构
1
监管机构数
成立时间
1999
终止
87
6.1%
招募中
250
17.5%
暂停
3
0.2%
撤回
42
2.9%
进行中（未招募）
116
8.1%
Unknown
145
10.2%
已完成
722
50.6%
Enrolling By Invitation
13
0.9%
尚未招募
50
3.5%
- Viral social media posts claim mebendazole is a hidden cancer cure, citing a 2021 Johns Hopkins patent on a mebendazole polymorph. - The patent's first inventor says mebendazole's oncology efficacy has not been established through the much-needed larger clinical trials. - Researchers report high doses of the anti-parasitic drug are safe and well tolerated in cancer patients, with a reasonable chance of being effective. - Experts caution that self-medicating carries risks including drug interactions, liver toxicity and anemia, and may delay evidence-based care.
- Geneseeq Canada becomes the first commercial genomic testing partner for UHN's SHERLOCK study, a large-scale prospective cancer research platform at Princess Margaret Cancer Centre. - The SHERLOCK study aims to enroll approximately 7,000 patients over five years across multiple solid tumors and hematologic malignancies to evaluate genomic technologies in cancer care. - Geneseeq will provide genomic profiling and molecular residual disease monitoring services for approximately 1,000 participants using its GeneseeqPrime®, Shielding® Ultra, and Hemasalus® assays. - The collaboration seeks to generate evidence on the biological and clinical significance of molecular residual disease, potentially informing future precision oncology strategies and clinical trial design.
- A long-term follow-up of a Health Canada-authorized phase I/IIa trial found that six of twelve knee osteoarthritis patients were responders to autologous bone marrow-derived MSC injections at 12 months, with benefits sustained at 24 months. - MSCs from responders demonstrated greater anti-inflammatory effects and dampened immune cell reactivity more effectively than MSCs from non-responders in lab-based tests. - Researchers identified 14 microRNAs present at different levels in responder versus non-responder MSCs, suggesting a potential biomarker panel for predicting MSC potency. - Baseline disease severity and inflammation did not correlate with therapy response, highlighting the importance of cell-intrinsic features over patient baseline characteristics.
- A CAMH study provides the first direct evidence of dopamine neuron loss in long COVID, with PET scans showing significantly reduced dopamine transporter markers across all major striatal regions. - Lower dopamine markers correlated with specific symptoms: reduced motivation linked to ventral striatum, slower movement to dorsal putamen, and poorer memory to caudate putamen. - A separate Finnish study found no evidence of widespread neuroinflammation in long COVID patients compared to healthy controls, though increased cellular activity in the hippocampus and amygdala was tied to anxiety and depression severity. - CAMH researchers plan a clinical trial evaluating dopamine-targeting medications, potentially shifting treatment strategies from anti-inflammatory approaches toward restoring dopamine function.
- Health Canada has approved DENOZA (denosumab injection), a biosimilar to Prolia, for treating postmenopausal women and men with osteoporosis at high risk for fracture. - The approval by Apotex addresses a significant public health need, as osteoporosis affects more than 2.3 million Canadians and remains an underdiagnosed condition. - DENOZA will be available in prefilled syringe format and aims to improve patient access to osteoporosis therapies while contributing to healthcare system sustainability. - Leading osteoporosis experts welcomed the approval as an important step in expanding treatment options and broadening available choices within the current treatment landscape.
- Avicanna has initiated a Phase I randomized, double-blind, placebo-controlled trial at the University of Calgary to evaluate dose-dependent effects of oral THC on anxiety and stress in 24 healthy adults. - The study will test three different THC doses (6mg, 9mg, and 15mg) using Avicanna's proprietary AVCN319301b capsules featuring Solid Self-Emulsifying Drug Delivery System technology. - Primary endpoints focus on validated psychometric assessments of anxiety and subjective response, with secondary measures including mood, cardiovascular parameters, and pharmacokinetic profiling. - The trial aims to generate high-resolution dose-response data to better define the therapeutic window of oral THC and characterize interindividual variability in response.
- Adela's tissue-free methylated ctDNA test demonstrated strong association with immunotherapy response, showing patients with decreased ctDNA levels had 31.77 times higher odds of objective response. - The validation study of 64 patients with advanced solid tumors receiving pembrolizumab showed significant improvements in progression-free survival and overall survival for patients with decreasing ctDNA levels. - The test addresses a critical unmet need for early response monitoring in immunotherapy, potentially enabling clinicians to make treatment decisions by cycle 3 rather than waiting for conventional imaging results. - Adela plans to commercialize the test later this year for clinical use in monitoring immunotherapy response across multiple solid tumor types.
- The LIGAND-AI consortium has launched with a €60 million budget to generate large, open datasets of protein-ligand interactions and train AI models for predicting drug candidates across thousands of human proteins. - Led by Pfizer and the Structural Genomics Consortium, the five-year project brings together 18 partners across nine countries to target rare neurological, cancer, and other unmet disease areas. - The initiative aims to transform the expensive and uncertain drug discovery process by combining advanced laboratory technologies with computational methods to create billions of data points for global researchers. - All generated data will be made freely available to the scientific community following FAIR principles, fostering an open discovery ecosystem for AI-driven therapeutic development.
- Avicanna announced publication of results from a prospective observational study evaluating physician-supervised medical cannabis use in chronic pain patients over 24 weeks. - The study demonstrated statistically significant improvements in pain interference, pain intensity, anxiety, depression, and quality of life measures among patients who remained on treatment. - While improvements did not meet minimal clinically important difference thresholds, the findings support medical cannabis potential in selected patients under healthcare provider supervision. - The ongoing Medical Cannabis Real-World Evidence study continues recruiting patients across seven Canadian provinces to evaluate outcomes in pain, sleep, anxiety, depression, and epilepsy.
- Arch Biopartners received ethics approval for St. Michael's Hospital to join its Phase II trial evaluating LSALT peptide for preventing cardiac surgery-associated acute kidney injury. - The international trial targets 240 patients and represents a potential first-in-class therapeutic approach for CS-AKI, which affects up to 30% of cardiac surgery patients. - LSALT peptide works by binding to the DPEP1 enzyme to inhibit organ inflammation, with previous studies showing statistically significant reductions in inflammatory biomarkers. - St. Michael's Hospital will become the ninth site globally and fourth Canadian site in the multi-center, randomized, placebo-controlled study.
